As of the latest Form 4 filed Jun 11, 2026.
What Biogen Inc insiders — officers, directors and 10% owners — have bought and sold in their own stock, straight from their SEC Form 4 filings. Values are shares × the reported transaction price where both are disclosed.
Buys plotted up, sells down; bar height is the disclosed dollar value (shares × reported price). Our Form 4 history is only complete from mid-2026, so early months are sparse — the series fills in as more filings land. Open-market purchases and sales only.
Newest filing first — the 73 most recent filings for BIIB.
| Filed | Trade date | Insider | Transaction | Shares | Price | Value | 10b5-1 | Filing |
|---|---|---|---|---|---|---|---|---|
| 2026-06-11 | 2026-06-09 | HAWKINS WILLIAM A Director | AAward | +1.50K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-06-11 | 2026-06-09 | SHERWIN STEPHEN A Director | AAward | +1.50K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-06-11 | 2026-06-09 | Rowinsky Eric K Director | AAward | +1.50K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-06-11 | 2026-06-09 | Mantas Jesus B Director | AAward | +1.50K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-06-11 | 2026-06-09 | LANGER SUSAN Director | AAward | +1.50K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-06-11 | 2026-06-09 | Patolawala Monish D Director | AAward | +1.50K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-06-11 | 2026-06-09 | Pangalos Menelas N Director | AAward | +1.50K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-06-11 | 2026-06-09 | Pangalos Menelas N, Director | MExercise | +2.37K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-06-11 | 2026-06-09 | Minor Lloyd Director | AAward | +1.50K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-06-11 | 2026-06-09 | Freire Maria C Director | AAward | +2.00K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-05-05 | 2026-05-01 | Keeney Adam Head of Corporate Development | FTax | −455.00 | $187.06 | $85.1K | No | Form 4 ↗ |
| 2026-05-05 | 2026-05-01 | Keeney Adam, Head of Corporate Development | MExercise | +939.00 | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-04-03 | 2026-04-01 | Godbout Sean Chief Accounting Officer | FTax | −54.00 | $183.78 | $9.92K | No | Form 4 ↗ |
| 2026-04-03 | 2026-04-01 | Godbout Sean, Chief Accounting Officer | MExercise | +181.00 | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-02-17 | 2026-02-12 | Murphy Nicole Head of Pharm Ops and Tech | PPurchase | +3.00 | $195.04 | $585.11 | No | Form 4 ↗ |
| 2026-02-10 | 2026-02-09 | Singhal Priya Head of Development | SSale | −2.66K | $199.83 | $532K | Yes (planned) | Form 4 ↗ |
| 2026-02-10 | 2026-02-06 | Viehbacher Christopher President and CEO | FTax | −6.62K | $201.18 | $1.33M | No | Form 4 ↗ |
| 2026-02-10 | 2026-02-06 | Viehbacher Christopher, President and CEO | MExercise | +15.5K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-02-10 | 2026-02-06 | Viehbacher Christopher, President and CEO | FTax | −4.36K | $201.18 | $876K | No | Form 4 ↗ |
| 2026-02-10 | 2026-02-06 | Viehbacher Christopher, President and CEO | MExercise | +9.01K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-02-10 | 2026-02-06 | Singhal Priya Head of Development | FTax | −1.41K | $201.18 | $284K | Yes (planned) | Form 4 ↗ |
| 2026-02-10 | 2026-02-06 | Singhal Priya, Head of Development | MExercise | +4.68K | $0.00 | $0.00 | Yes (planned) | Form 4 ↗ |
| 2026-02-10 | 2026-02-06 | Singhal Priya, Head of Development | FTax | −1.06K | $201.18 | $212K | Yes (planned) | Form 4 ↗ |
| 2026-02-10 | 2026-02-06 | Singhal Priya, Head of Development | MExercise | +2.22K | $0.00 | $0.00 | Yes (planned) | Form 4 ↗ |
| 2026-02-10 | 2026-02-06 | Murphy Nicole Head of Pharm Ops and Tech | FTax | −1.41K | $201.18 | $283K | No | Form 4 ↗ |
| 2026-02-10 | 2026-02-06 | Murphy Nicole, Head of Pharm Ops and Tech | MExercise | +4.68K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-02-10 | 2026-02-06 | Murphy Nicole, Head of Pharm Ops and Tech | FTax | −914.00 | $201.18 | $184K | No | Form 4 ↗ |
| 2026-02-10 | 2026-02-06 | Murphy Nicole, Head of Pharm Ops and Tech | MExercise | +1.94K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-02-10 | 2026-02-06 | Murphy Nicole, Head of Pharm Ops and Tech | FTax | −1.02K | $201.18 | $205K | No | Form 4 ↗ |
| 2026-02-10 | 2026-02-06 | Murphy Nicole, Head of Pharm Ops and Tech | MExercise | +2.10K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-02-10 | 2026-02-06 | Kramer Robin Chief Financial Officer | FTax | −1.06K | $201.18 | $214K | No | Form 4 ↗ |
| 2026-02-10 | 2026-02-06 | Kramer Robin, Chief Financial Officer | MExercise | +3.51K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-02-10 | 2026-02-06 | Kramer Robin, Chief Financial Officer | FTax | −207.00 | $201.18 | $41.6K | No | Form 4 ↗ |
| 2026-02-10 | 2026-02-06 | Kramer Robin, Chief Financial Officer | MExercise | +703.00 | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-02-10 | 2026-02-06 | Kramer Robin, Chief Financial Officer | FTax | −273.00 | $201.18 | $54.9K | No | Form 4 ↗ |
| 2026-02-10 | 2026-02-06 | Kramer Robin, Chief Financial Officer | MExercise | +789.00 | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-02-10 | 2026-02-06 | Keeney Adam Head of Corporate Development | FTax | −994.00 | $201.18 | $200K | No | Form 4 ↗ |
| 2026-02-10 | 2026-02-06 | Keeney Adam, Head of Corporate Development | MExercise | +3.28K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-02-10 | 2026-02-06 | Keeney Adam, Head of Corporate Development | FTax | −589.00 | $201.18 | $118K | No | Form 4 ↗ |
| 2026-02-10 | 2026-02-06 | Keeney Adam, Head of Corporate Development | MExercise | +1.80K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-02-10 | 2026-02-06 | Izzar Rachid Head of Global Product Strat. | FTax | −775.00 | $201.18 | $156K | No | Form 4 ↗ |
| 2026-02-10 | 2026-02-06 | Izzar Rachid, Head of Global Product Strat. | MExercise | +3.04K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-02-10 | 2026-02-06 | Izzar Rachid, Head of Global Product Strat. | FTax | −458.00 | $201.18 | $92.1K | No | Form 4 ↗ |
| 2026-02-10 | 2026-02-06 | Izzar Rachid, Head of Global Product Strat. | MExercise | +1.80K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-02-10 | 2026-02-06 | Izzar Rachid, Head of Global Product Strat. | FTax | −805.00 | $201.18 | $162K | No | Form 4 ↗ |
| 2026-02-10 | 2026-02-06 | Izzar Rachid, Head of Global Product Strat. | MExercise | +2.04K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-02-10 | 2026-02-06 | Grogan Jane Head of Research | FTax | −584.00 | $201.18 | $117K | No | Form 4 ↗ |
| 2026-02-10 | 2026-02-06 | Grogan Jane, Head of Research | MExercise | +1.87K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-02-10 | 2026-02-06 | Grogan Jane, Head of Research | FTax | −407.00 | $201.18 | $81.9K | No | Form 4 ↗ |
| 2026-02-10 | 2026-02-06 | Grogan Jane, Head of Research | MExercise | +1.39K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-02-10 | 2026-02-06 | Gregory Ginger EVP, Human Resources | FTax | −1.13K | $201.18 | $228K | No | Form 4 ↗ |
| 2026-02-10 | 2026-02-06 | Gregory Ginger, EVP, Human Resources | MExercise | +3.75K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-02-10 | 2026-02-06 | Gregory Ginger, EVP, Human Resources | FTax | −666.00 | $201.18 | $134K | No | Form 4 ↗ |
| 2026-02-10 | 2026-02-06 | Gregory Ginger, EVP, Human Resources | MExercise | +1.80K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-02-10 | 2026-02-06 | Gregory Ginger, EVP, Human Resources | FTax | −791.00 | $201.18 | $159K | No | Form 4 ↗ |
| 2026-02-10 | 2026-02-06 | Gregory Ginger, EVP, Human Resources | MExercise | +1.64K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-02-10 | 2026-02-06 | Godbout Sean Chief Accounting Officer | FTax | −180.00 | $201.18 | $36.2K | No | Form 4 ↗ |
| 2026-02-10 | 2026-02-06 | Godbout Sean, Chief Accounting Officer | MExercise | +517.00 | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-02-10 | 2026-02-06 | Godbout Sean, Chief Accounting Officer | FTax | −103.00 | $201.18 | $20.7K | No | Form 4 ↗ |
| 2026-02-10 | 2026-02-06 | Godbout Sean, Chief Accounting Officer | MExercise | +305.00 | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-02-10 | 2026-02-06 | Godbout Sean, Chief Accounting Officer | FTax | −76.00 | $201.18 | $15.3K | No | Form 4 ↗ |
| 2026-02-10 | 2026-02-06 | Godbout Sean, Chief Accounting Officer | MExercise | +257.00 | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-02-10 | 2026-02-06 | ALEXANDER SUSAN H EVP Chief Legal Officer | FTax | −1.51K | $201.18 | $305K | No | Form 4 ↗ |
| 2026-02-10 | 2026-02-06 | ALEXANDER SUSAN H, EVP Chief Legal Officer | MExercise | +4.92K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-02-10 | 2026-02-06 | ALEXANDER SUSAN H, EVP Chief Legal Officer | FTax | −931.00 | $201.18 | $187K | No | Form 4 ↗ |
| 2026-02-10 | 2026-02-06 | ALEXANDER SUSAN H, EVP Chief Legal Officer | MExercise | +1.94K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-02-10 | 2026-02-06 | ALEXANDER SUSAN H, EVP Chief Legal Officer | FTax | −1.06K | $201.18 | $213K | No | Form 4 ↗ |
| 2026-02-10 | 2026-02-06 | ALEXANDER SUSAN H, EVP Chief Legal Officer | MExercise | +2.19K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-02-03 | 2026-02-02 | Singhal Priya Head of Development | SSale | −748.00 | $179.30 | $134K | Yes (planned) | Form 4 ↗ |
| 2026-02-03 | 2026-01-30 | Singhal Priya, Head of Development | FTax | −582.00 | $179.89 | $105K | Yes (planned) | Form 4 ↗ |
| 2026-02-03 | 2026-01-30 | Singhal Priya, Head of Development | MExercise | +1.83K | $0.00 | $0.00 | Yes (planned) | Form 4 ↗ |
| 2024-05-03 | 2024-05-01 | Keeney Adam Head of Corporate Development | FTax | −276.00 | $216.13 | $59.7K | No | Form 4 ↗ |
| 2024-05-03 | 2024-05-01 | Keeney Adam, Head of Corporate Development | MExercise | +938.00 | $0.00 | $0.00 | No | Form 4 ↗ |
Insiders — a company’s officers, directors and holders of more than 10% of its stock — must report any trade in that stock to the SEC on a Form 4 within two business days. Each row here is one transaction from those filings.
The transaction code tells you what happened: Purchase (P) and Sale (S) are open-market trades — the ones markets watch most; Award (A) is a granted stock or unit, Option exercise (M) converts options into shares, and Gift (G) is a transfer for no consideration. Awards, exercises and gifts are largely compensation or administrative, not a directional bet.
One caveat on sales: many are made under a Rule 10b5-1 plan scheduled months in advance, so a sale is not automatically a bearish signal. Insider activity is a noisy input — read it alongside the filings, not on its own.
See also BIIB’s full analysis or the market-wide insider trading feed. The tabs above jump to BIIB’s other SEC data.
Source: SEC Form 4 filings for BIIB, parsed from EDGAR. Transaction prices are as reported in the filing — SEC public-domain data, not market quotes. Values are shares × reported price where both are disclosed; grants and gifts often carry no price. A delayed record of what insiders reported, not a live position or a recommendation.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.